Sabrina Toews

Sabrina Toews

Auto-generated profile, based on publicly available information

Sabrina Toews

Institute For Organic Chemistry and Chemical Biology Goethe University Frankfurt Frankfurt am Main Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2024 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
STSabrina Toews
Sabrina Toews
AWAnna Wacker
Anna Wacker
EFEdgar Faison
Edgar Faison
EDElke Duchardt-Ferner
Elke Duchardt-Ferner
CRChristian Richter
Christian Richter
HSHarald Schwalbe
Harald Schwalbe
We present the nuclear magnetic resonance spectroscopy (NMR) solution structure of the 5′-terminal stem loop 5_SL1 (SL1) of the SARS-CoV-2 genome. SL1 contains two A-form helical elements and two regions with non-canonical structure, namely an apical pyrimidine-rich loop and an asymmetric internal loop with one and two nucleotides at the 5′- and 3′-terminal part of the sequence, respectively. The conformational ensemble representing the averaged solution structure of SL1 was validated using NMR residual dipolar coupling (RDC) and small-angle X-ray scattering (SAXS) data. We show that the internal loop is the major binding site for fragments of low molecular weight. This internal loop of SL1 can be stabilized by an A12–C28 interaction that promotes the transient formation of an A+•C base pair. As a consequence, the pKa of the internal loop adenosine A12 is shifted to 5.8, compared to a pKa of 3.63 of free adenosine. Furthermore, applying a recently developed pH-differential mutational profiling (PD-MaP) approach, we not only recapitulated our NMR findings of SL1 but also unveiled multiple sites potentially sensitive to pH across the 5′-UTR of SARS-CoV-2.

5 February 2025 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
BCBetül Ceylan
Betül Ceylan
JAJennifer Adam
Jennifer Adam
STSabrina Toews
Sabrina Toews
FKFrank Kaiser
Frank Kaiser
JDJonas Dörr
Jonas Dörr
HSHarald Schwalbe
Harald Schwalbe
Targeting the RNA genome of SARS‐CoV‐2 is a viable option for antiviral drug development. We explored three ligand binding sites of the core pseudoknot RNA of the SARS‐CoV‐2 frameshift element. We iteratively optimized ligands, based on improved affinities, targeting these binding sites and report on structural and dynamic properties of the three identified binding sites. Available experimental 3D structures of the pseudoknot element were compared to SAXS and NMR data to validate its dominant folding state in solution. In order to experimentally map in silico predicted binding sites, NMR assignments of the majority of nucleobases were achieved by segmental labeling of the pseudoknot RNA and isotope‐filtered NMR experiments at 1.2 GHz, demonstrating the value of NMR spectroscopy to supplement modelling and docking data. Optimized ligands with enhanced affinity were shown to specifically inhibit frameshifting without affecting 0‐frame translation in cell‐free translation assays, establishing the frameshift element as target for drug‐like ligands of low molecular weight.

29 November 2025 in ChemBioChem
Verified
Journal Article
Open access
STSabrina Toews
Sabrina Toews
BCBetül Ceylan
Betül Ceylan
AWAnna Wacker
Anna Wacker
MKMegan Ken
Megan Ken
HSHarald Schwalbe
Harald Schwalbe
An approach combining virtual and nuclear magnetic resonance (NMR)‐based screening is presented here to identify low molecular weight molecules (small molecules) targeting viral RNA elements from the SARS‐CoV‐2 genome. The so‐called high‐resolution RNA structural Fragment Assembly of RNA with Full‐Atom Refinement 2 (FARFAR2) ensembles of the conserved 5 ′ ‐terminal stem‐loop 1 (SL1) and the pseudoknot of the –1 programed frameshift element are used as targets for binding of small molecules of three different virtual libraries of compounds. The resulting hits predicted by virtual screening are probed for their binding to the two RNA elements by ligand‐ and target‐based NMR experiments. The results demonstrate that the integration of virtual and experimental NMR screening efficiently identifies RNA‐binding small molecules as start molecular entities to advance RNA‐targeted antiviral therapies in an efficient manner. The strategy does not only apply to SARS‐CoV‐2, but also provides a rapid, highly specific route to discovering therapeutics for other RNA‐based pathogens, highlighting the critical role of RNA structural data in enriching virtual drug discovery efforts.

23 April 2026 in Nucleic Acids Research
Verified
Journal Article
Open access
JSJulian B Schoth
Julian B Schoth
ISInge Schwedt
Inge Schwedt
SPSusanne Philipp
Susanne Philipp
STSabrina Toews
Sabrina Toews
LSLeonie Schübel
Leonie Schübel
JWJulia E Weigand
Julia E Weigand
Several SARS-CoV-2 variants have evolved with clinical relevance due to their structural and functional impact on viral proteins and genomic RNA structures. A comprehensive structural and functional characterization of single-nucleotide variations in the 5′-untranslated region (UTR) of SARS-CoV-2 has remained elusive. The co-evolution of 5′-UTR stem-loop 1 (SL1) and non-structural protein (nsp) 1 mutants are of particular importance, as both are key in directing the translation of the viral genome. Here, we investigate the structure and function of the most frequently emerging mutations in SL1 and nsp1. Mutation C21U in the apical loop of SL1 shows changed loop dynamics and reduced escape from repression by nsp1 mutants. Mutation analyses of the pyrimidine loop and the apical helix of SL1 identify preferred sequence motifs for escape from nsp1 repression. Importantly, sequence preferences are governed by the structural features, with suboptimal pyrimidine sequences escaping repression when presented in the SL1 context. Compared to the nsp1 wild type (wt), the currently circulating nsp1 linker variant S135R is much more sensitive toward sequence and structure variations of the apical loop of SL1. Thus, our study provides new insights into the structure–function relationship and co-evolution between viral RNA structures and viral proteins.

5 February 2025 in Angewandte Chemie
Verified
Journal Article
Open access
BCBetül Ceylan
Betül Ceylan
JAJennifer Adam
Jennifer Adam
STSabrina Toews
Sabrina Toews
FKFrank Kaiser
Frank Kaiser
JDJonas Dörr
Jonas Dörr
HSHarald Schwalbe
Harald Schwalbe
Targeting the RNA genome of SARS‐CoV‐2 is a viable option for antiviral drug development. We explored three ligand binding sites of the core pseudoknot RNA of the SARS‐CoV‐2 frameshift element. We iteratively optimized ligands, based on improved affinities, targeting these binding sites and report on structural and dynamic properties of the three identified binding sites. Available experimental 3D structures of the pseudoknot element were compared to SAXS and NMR data to validate its dominant folding state in solution. In order to experimentally map in silico predicted binding sites, NMR assignments of the majority of nucleobases were achieved by segmental labeling of the pseudoknot RNA and isotope‐filtered NMR experiments at 1.2 GHz, demonstrating the value of NMR spectroscopy to supplement modelling and docking data. Optimized ligands with enhanced affinity were shown to specifically inhibit frameshifting without affecting 0‐frame translation in cell‐free translation assays, establishing the frameshift element as target for drug‐like ligands of low molecular weight.

20 August 2026 in Current Protocols
Verified
Journal Article
Open access
STSabrina Toews
Sabrina Toews
MKMegan Ken
Megan Ken
HSHarald Schwalbe
Harald Schwalbe
Targeting structured RNA elements with small molecules has emerged as a promising yet technically challenging strategy for antiviral drug discovery. Here, we present a comprehensive and experimentally validated workflow for the integrative in silico and in vitro screening of RNA‐binding small molecules. The approach is exemplified using conserved RNA elements from the SARS‐CoV‐2 genome, including the 5’‐terminal stem‐loop 1 and the programmed –1 ribosomal frameshift pseudoknot, but is broadly applicable to other structured RNAs. The workflow integrates high‐resolution RNA structural ensemble generation with virtual screening (VS) and nuclear magnetic resonance (NMR)‐based experimental validation. Conformational ensembles generated by fragment‐assembly approaches serve as targets for docking chemically diverse fragments and lead‐like libraries. Top‐ranked compounds are prioritized through consensus scoring and evaluated using ligand‐ and RNA‐observed NMR experiments to confirm binding, characterize interaction modes, and assess specificity. Such ranking allows for NMR‐guided fragment optimization, which enables systematic improvement of solubility, affinity, and selectivity through iterative medicinal chemistry in the pharmaceutical pipeline. Detailed procedures are provided for library preparation, ensemble‐based VS, hit validation, data interpretation, and progression toward functional assays, together with practical considerations, quality‐control parameters, and troubleshooting guidance to ensure reproducibility. By combining computational and experimental strategies that select for high‐specificity ligands within a unified framework, this set of protocols accelerates the discovery and optimization of RNA‐targeting small molecules and provides a scalable platform for RNA‐focused drug discovery. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : Target and library preparation for virtual screening Basic Protocol 2 : Ensemble‐based virtual screening of low‐molecular‐weight compounds against RNA targets Basic Protocol 3 : Comparative hit prioritization and selectivity filtering for RNA‐binding small molecules Basic Protocol 4 : Preparation of RNA samples for in vitro validation of small‐molecule binding Basic Protocol 5 : NMR‐based in vitro screening of RNA–small molecule interactions Support Protocol : Preparation of ligand stocks and NMR‐based quality control Basic Protocol 6 : Characterization and prioritization of validated RNA‐binding hits